Dana-Farber Cancer Institute
S

Sexual Health and Sexual Recovery for Adults Living With mBC

By Dana-Farber Cancer Institute FEATURING Sharon Bober
By Dana-Farber Cancer Institute FEATURING Sharon Bober
0 views
March 4, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

Recommended

AUTOPLAY
25:08
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

Feat. S. Tolaney, H. Rugo
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
36:18
Insights from ESMO Breast 2024 Annual Meeting

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Feat. H. Rugo
06:10
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Summary: "Is There a Role for Combining ADCs W…

Feat. S. Tolaney
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
33:44
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive &a…

Feat. S. Tolaney, H. Rugo
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
10:09
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "Pooled Analysis of T-DXd Retreatmen…

Feat. H. Rugo
05:35
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "IMpassion132 Trial - Is There a Rol…

Feat. S. Tolaney
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
09:26
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "DESTINY-Breast06 - T-DXd vs. Physician’s …

Feat. G. Curigliano
12:24
Stanford Medicine

HR+ mBC: CDK4/6i Progression Management

Feat. M. Dolezal
29:45
Miami Cancer Institute Precision Oncology Symposium

Precision Therapy for HR+/HER2- mBC

Feat. J. O'Shaughnessy
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
11:19
Adam Brufsky

HER2+ mBC: The Role of TDM-1

35:14
OncoAlert

Advanced TNBC Updates

Feat. H. Rugo
14:54
Grace Choong

Resistance Mutations in HR+ mBC After 1L ET + CDK4/6i: Next Lines an…

13:23
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…

Feat. S. Hurvitz
23:52
Cleveland Clinic Taussig Cancer Institute

Targetable Mutations in HR+/HER2- mBC

Feat. M. Kruse